Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.86 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.86 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.86 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.86 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.86 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.86 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.86 |
| ▸ | FECH | P22830 | 1/20 | 0.66 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ku-0063794 SCHEMBL290208 | 0.93 | MTOR (1.00) | MTORKCNH2PIK3CARICTORRPTOR | |
| Ku-0063794 SCHEMBL29454796 | 0.93 | MTOR (1.00) | MTORKCNH2PIK3CARICTORRPTOR | |
| Ku-0063794 SCHEMBL290211 | 0.93 | MTOR (1.00) | MTORKCNH2PIK3CARICTORRPTOR | |
| Ku-0063794 SCHEMBL29350060 | 0.93 | MTOR (1.00) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL2926233 | 0.91 | MTOR (0.94) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL10287646 | 0.91 | MTOR (0.86) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL22787101 | 0.91 | MTOR (0.84) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL18434385 | 0.89 | MTOR (0.69) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL22030453 | 0.86 | MTOR (0.89) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL2908254 | 0.86 | MTOR (0.89) | MTORKCNH2PIK3CARICTORRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316137-A1 | Methods and Compositions for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316137-A1 | Methods and Compositions for Treating Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MKI67 | MTOR 1596/4885KCNH2 3538/4885PIK3CA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.